High-dose tirzepatide is associated with superior HbA1c reduction and weight loss compared with semaglutide in type 2 diabetes and obesity.

Medications aren’t lifelong contracts. You can switch from one to another — if it’s safe for you to do so and under the guidance of a healthcare provider, of course. So, if you’re taking tirzepatide ...

Wegovy (semaglutide) and Zepbound (tirzepatide) are commonly prescribed medications for weight management. Semaglutide, the first weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist, ...

Using medications for weight loss is becoming more common. Doctors sometimes prescribe newer type 2 diabetes drugs to help with weight management. This use is “off-label,” meaning that doctors ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and ...

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and a valid prescription can purchase 2.5 mg and 5 mg single-dose vials of tirzepatide. The ...

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years. Despite its clinical success, its precise molecular and cellular ...

Lilly, the pharmaceutical giant, would love for you to believe that tirzepatide is the silver bullet we've all been waiting for — slashing your diabetes risk by 94% while you shed pounds. But dig a ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Tirzepatide is associated with lower all-cause mortality and reduced adverse gastrointestinal events compared with ...

Compounded tirzepatide contains the same active ingredient as Mounjaro but may differ in quality, ingredients, and dosage. The Food and Drug Administration (FDA) does not regulate its safety, ...

The once-weekly injectable tirzepatide (Mounjaro, Zepbound) was associated with reduced blood pressure (BP) in a prospective substudy of the SURMOUNT-1 trial. Depending on the dose of the combination ...